StreetInsider.com News Articles

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

Thu, 10 Sep 2026 15:54:00 -0400

Interactive mobile experience champions evidence-based science, fights misinformation and connects with communities in support of the future of innovation

Bayer kicks off a multi-year, nationwide "Science Delivers" tour running through 2027 across states including California, Iowa, Pennsylvania, Ohio, Michigan, Indiana, Missouri, New York, New Jersey and Washington, D.C.
Custom mobile experience engages scientists, farmers, researchers and students on health innovation, agricultural science and the future of discovery
Campaign responds to a Harris Poll survey of 2,023 US adults commissioned by Bayer, "Science Under Siege," March 2026, which found 82% worry about their own and their family's wellbeing due to science and health

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

Thu, 10 Sep 2026 15:54:00 -0400

Interactive mobile experience champions evidence-based science, fights misinformation and connects with communities in support of the future of innovation

Bayer kicks off a multi-year, nationwide "Science Delivers" tour running through 2027 across states including California, Iowa, Pennsylvania, Ohio, Michigan, Indiana, Missouri, New York, New Jersey and Washington, D.C.
Custom mobile experience engages scientists, farmers, researchers and students on health innovation, agricultural science and the future of discovery
Campaign responds to a Harris Poll survey of 2,023 US adults commissioned by Bayer, "Science Under Siege," March 2026, which found 82% worry about their own and their family's wellbeing due to science and health

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

Thu, 10 Sep 2026 15:54:00 -0400

Interactive mobile experience champions evidence-based science, fights misinformation and connects with communities in support of the future of innovation

Bayer kicks off a multi-year, nationwide "Science Delivers" tour running through 2027 across states including California, Iowa, Pennsylvania, Ohio, Michigan, Indiana, Missouri, New York, New Jersey and Washington, D.C.
Custom mobile experience engages scientists, farmers, researchers and students on health innovation, agricultural science and the future of discovery
Campaign responds to a Harris Poll survey of 2,023 US adults commissioned by Bayer, "Science Under Siege," March 2026, which found 82% worry about their own and their family's wellbeing due to science and health

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

Thu, 10 Sep 2026 15:54:00 -0400

Interactive mobile experience champions evidence-based science, fights misinformation and connects with communities in support of the future of innovation

Bayer kicks off a multi-year, nationwide "Science Delivers" tour running through 2027 across states including California, Iowa, Pennsylvania, Ohio, Michigan, Indiana, Missouri, New York, New Jersey and Washington, D.C.
Custom mobile experience engages scientists, farmers, researchers and students on health innovation, agricultural science and the future of discovery
Campaign responds to a Harris Poll survey of 2,023 US adults commissioned by Bayer, "Science Under Siege," March 2026, which found 82% worry about their own and their family's wellbeing due to science and health

FDA grants Bayer's HYRNUO accelerated approval as first-line NSCLC therapy

Wed, 09 Sep 2026 22:22:44 -0400

The U.S. Food and Drug Administration has granted accelerated approval to Bayer's HYRNUO (sevabertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

The approval, based on a Bayer press release, follows Priority Review and Breakthrough Therapy Designation. HYRNUO is an oral, reversible, small molecule tyrosine kinase inhibitor.

The FDA's decision is based on results from Cohort F of the ongoing Phase I/II SOHO-01 trial, which enrolled 69 treatment-naïve patients. The objective response rate was 75% (95% CI:

FDA grants Bayer's HYRNUO accelerated approval as first-line NSCLC therapy

Wed, 09 Sep 2026 22:22:44 -0400

The approval, based on a Bayer press release, follows Priority Review and Breakthrough Therapy Designation. HYRNUO is an oral, reversible, small molecule tyrosine kinase inhibitor.

The FDA's decision is based on results from Cohort F of the ongoing Phase I/II SOHO-01 trial, which enrolled 69 treatment-naïve patients. The objective response rate was 75% (95% CI:

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

Wed, 09 Sep 2026 22:21:00 -0400

First-line approval of HYRNUO® (sevabertinib) for patients with advanced HER2-mutated non-small cell lung cancer (NSCLC) follows U.S. Food and Drug Administration (FDA) Priority Review and Breakthrough Therapy Designation
Approval is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety of HYRNUO in patients with advanced HER2-mutated NSCLC

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer announced today that following Priority Review and Breakthrough Therapy Designation, the U.S. Food and Drug Administration (FDA) has granted accelerated approval for HYRNUO® (sevabertinib), for the first-line treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

Wed, 09 Sep 2026 22:21:00 -0400

First-line approval of HYRNUO® (sevabertinib) for patients with advanced HER2-mutated non-small cell lung cancer (NSCLC) follows U.S. Food and Drug Administration (FDA) Priority Review and Breakthrough Therapy Designation
Approval is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety of HYRNUO in patients with advanced HER2-mutated NSCLC

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

Wed, 09 Sep 2026 22:21:00 -0400

First-line approval of HYRNUO® (sevabertinib) for patients with advanced HER2-mutated non-small cell lung cancer (NSCLC) follows U.S. Food and Drug Administration (FDA) Priority Review and Breakthrough Therapy Designation
Approval is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety of HYRNUO in patients with advanced HER2-mutated NSCLC

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

Wed, 09 Sep 2026 22:21:00 -0400

First-line approval of HYRNUO® (sevabertinib) for patients with advanced HER2-mutated non-small cell lung cancer (NSCLC) follows U.S. Food and Drug Administration (FDA) Priority Review and Breakthrough Therapy Designation
Approval is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety of HYRNUO in patients with advanced HER2-mutated NSCLC

Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026